Alliance for Patient Access / What's New / *** PRESS RELEASE*** Summit on Biologics & Biosimilars Convenes Physicians, Advocates and Officials to Discuss Policy Issues

*** PRESS RELEASE*** Summit on Biologics & Biosimilars Convenes Physicians, Advocates and Officials to Discuss Policy Issues

WASHINGTON – On Thursday, April 6 the Institute for Patient Access and Biologics Prescribers Collaborative, a project of the Alliance for Patient Access, will host the 2nd Annual National Policy and Advocacy Summit on Biologics and Biosimilars in Washington, DC. The summit will explore timely state and federal policy issues impacting patient access to approved biologic therapies and their biosimilar counterparts. The summit, held at the Ronald Reagan Building and International Trade Center, will feature remarks by Senator Bill Cassidy, M.D. (R-La.), FDA official Leah Christl, Ph.D, and Shannon Miller, decorated Olympic gymnast and cancer survivor.

Policy issues to be considered at the summit include the FDA guidance governing interchangeability, limitations on non-medical switching, the WHO proposal for distinct non-proprietary names and phamacovigilence. The summit will also feature an international panel discussion focused on the policies impacting access to biologics and biosimilars in both Europe and Latin America.

Summit attendees include health care providers, patient advocates and representatives from national physician associations.

Summit panelists include: Kathleen Arntsen, Lupus and Allied Diseases Association; Neil Betteridge, UK; Arturo Loaiza-Bonilla, M.D., Global Alliance for Patient Access; Dr. Leah Christl, Center for Drug Evaluation and Research, FDA; Nicholas Florko, Inside Health Policy; Harry Gewanter, M.D., Alliance for Safe Biologic Medicines; Stephen Marmaras, Eva Maria Ruiz de Castilla, Global Alliance for Patient Access Latin America; Global Healthy Living Foundation; Greg Schimizzi, M.D., Biologics Prescribers Collaborative; Patrick Stone, National Psoriasis Foundation.

The Biologic Prescribers Collaborative brings together leading medical societies whose members regularly prescribe biological medicines.  The group educates and makes comment on major policy issues. The Biologics Prescribers Collaborative pursues sound policies that promote safe use of all biologics, including biosimilars, for all patients.

The summit begins on Thursday, April 6 at 9:15 a.m.

The summit is open to the press. Press interested in attending should RSVP to Susan Hepworth at [email protected] no later than Wednesday, April 5.


Biologics Prescribers Collaborative

Alliance for Patient Access


About AfPA Digital

The Alliance for Patient Access is a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care.
Back to Top